GRX-917 is a Transformative Treatment for Anxiety, Depression and Chronic Pain, without Addiction Potential and with Minimal Side Effects

GABA Brain Image
GABA Brain Receptor

GRX-917 works by inducing the production of endogenous neurosteroids (such as allopregnanolone) and inhibiting NLRP3 inflammation.

These important mechanisms of action could benefit a broad range of neuropsychiatric, neurological and auto-immune disorders.

GRX-917 is ready to initiate Phase 2/3 registration studies in anxiety in 2025.

Decades of clinical data with GRX-917’s predecessor analog has demonstrated excellent safety and anxiolytic efficacy comparable to leading benzodiazepines.